导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.54% | 3561/4773 |
| 近一周 | -2.21% | 3582/5465 |
| 近一月 | -1.43% | 1151/5421 |
| 近一季 | 0.58% | 888/5231 |
| 近半年 | -5.49% | 3038/4920 |
| 近一年 | -9.92% | 3414/4394 |
| 近两年 | 38.78% | 1953/2954 |
| 近三年 | 36.80% | 854/2253 |
| 成立以来 | 44.19% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.96% 3733/4961 |
-8.56% 3897/5312 |
- - |
- - |
| 2025 | 27.09% 1584/4813 |
15.03% 191/3635 |
4.03% 883/4076 |
11.94% 3113/4524 |
-5.12% 3516/4813 |
| 2024 | 23.53% 330/3463 |
-1.41% 1222/2808 |
9.94% 45/3014 |
14.99% 1851/3129 |
-0.89% 1539/3463 |
| 2023 | -10.25% 1280/2656 |
0.39% 1733/2280 |
0.05% 347/2385 |
-8.17% 1672/2515 |
-2.69% 515/2655 |
| 2022 | -4.45% 95/2207 |
-6.69% 223/1919 |
6.08% 770/2016 |
-14.55% 1111/2113 |
12.97% 113/2208 |
| 2021 | -12.28% 1127/1822 |
4.46% 148/1255 |
0.13% 1110/1330 |
-11.28% 1261/1466 |
-5.47% 1511/1822 |
| 2020 | -4.75% 964/1250 |
-13.27% 161/280 |
5.31% 221/295 |
-7.17% 1130/1164 |
12.34% 476/1184 |
| 2019 | 12.72% 715/1092 |
- - |
- - |
- - |
- - |
| 2018 | -8.00% 66/834 |
- - |
- - |
- - |
- - |
| 2017 | 28.29% 79/714 |
- - |
- - |
- - |
- - |
| 2016 | 8.04% 4/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏沪港通恒生ETF联接A VS. 长安沪深300非周期A(740101) |